ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy

Trial Timeline

Oct 1, 2010 → May 1, 2011

NCT ID

NCT01239758

About ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)

ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03) is a phase 2 stage product being developed by Merck for Duchenne Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01239758. Target conditions include Duchenne Muscular Dystrophy.

What happened to similar drugs?

2 of 20 similar drugs in Duchenne Muscular Dystrophy were approved

Approved (2) Terminated (8) Active (11)

❌Tadalafil + PlaceboEli LillyPhase 3

🔄Viltolarsen + PlaceboNippon ShinyakuPhase 3

🔄ViltolarsenNippon ShinyakuPhase 3

❌fordadistrogene movaparvovecPfizerPhase 3

🔄Ataluren + PlaceboPTC TherapeuticsPhase 3

🔄Ataluren + PLACEBOPTC TherapeuticsPhase 3

🔄AtalurenPTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01239758	Phase 2	Terminated	Oct 1, 2010	May 1, 2011	Duchenne Muscular Dystrophy

Competing Products

20 competing products in Duchenne Muscular Dystrophy

See all competitors

Product	Company	Stage	Hype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)	Biotrial	Phase 1/2	29
ENTR-601-44 + ENTR-601-44 - matching placebo	Entrada Therapeutics	Phase 1/2	29
ENTR-601-45 + ENTR-601-45 - matching placebo	Entrada Therapeutics	Phase 1/2	29
Tadalafil + Placebo	Eli Lilly	Phase 3	32
DS-5141b	Daiichi Sankyo	Phase 2	39
DS-5141b	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
scAAV9.U7.ACCA	Astellas Pharma	Phase 1/2	32
NS-065/NCNP-01	Nippon Shinyaku	Phase 2	35
Viltolarsen + Placebo	Nippon Shinyaku	Phase 3	40
Viltolarsen	Nippon Shinyaku	Phase 2	35
NS-089/NCNP-02 + NS-089/NCNP-02	Nippon Shinyaku	Phase 2	39
NS-065/NCNP-01	Nippon Shinyaku	Phase 1	29
NS-050/NCNP-03 + Placebo	Nippon Shinyaku	Phase 1/2	39
NS-089/NCNP-02	Nippon Shinyaku	Phase 2	42
Viltolarsen	Nippon Shinyaku	Phase 3	36
NS-089/NCNP-02	Nippon Shinyaku	Phase 1/2	32
NS-065/NCNP-01 + Placebo	Nippon Shinyaku	Phase 2	35
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wk	Merck	Phase 2	27
Satralizumab	Roche	Phase 2	42